Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Defining the survival benchmark for breast cancer patients with systemic relapse.
Zeichner SB, Ambros T, Zaravinos J, Montero AJ, Mahtani RL, Ahn ER, Mani A, Markward NJ, Vogel CL. Zeichner SB, et al. Among authors: mahtani rl. Breast Cancer (Auckl). 2015 Apr 15;9:9-17. doi: 10.4137/BCBCR.S23794. eCollection 2015. Breast Cancer (Auckl). 2015. PMID: 25922577 Free PMC article.
Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.
Zeichner SB, Herna S, Mani A, Ambros T, Montero AJ, Mahtani RL, Ahn ER, Vogel CL. Zeichner SB, et al. Among authors: mahtani rl. Breast Cancer Res Treat. 2015 Oct;153(3):617-24. doi: 10.1007/s10549-015-3564-3. Epub 2015 Sep 10. Breast Cancer Res Treat. 2015. PMID: 26358708 Review.
When Can a Salvage Therapy (T-DM1) Take the Lead?
Mahtani RL, Vogel CL. Mahtani RL, et al. J Clin Oncol. 2016 Oct 10;34(29):3492-3494. doi: 10.1200/JCO.2016.68.4241. J Clin Oncol. 2016. PMID: 27432926 No abstract available.
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). Abraham J, et al. Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4. Breast Cancer Res Treat. 2018. PMID: 29725889 Review.
48 results